MedTrace Logo

Phase II Study of RR110 in Patients With Active Crohn's Disease

NCT00417391 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2008-05-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics profile of 1 and 4 mg/kg/day RR110 administrated orally for 8 weeks in patients with active Crohn's disease.

Conditions

Interventions

DRUG

RR110 (Tamibarotene)

1 mg RR110

DRUG

RR110 (Tamibarotene)

4 mg RR110

Sponsors & Collaborators

  • R&R Inc.

    lead INDUSTRY

Principal Investigators

  • Toshifumi Hibi, M.D., Ph.D. · Keio University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00417391 on ClinicalTrials.gov